FDA Approves Two-In-One Diabetes Treatment For Type 2

By Brenda Neugent The U.S. Food and Drug Administration recently approved a two-in-one diabetes treatment that combines two type 2 treatments. Glyxambi combines empagliflozin, a sodium glucose cotransporter-2 inhibitor that blocks the absorption of excess glucose by the kidneys so it is released through urine, and linagliptin, a DPP-4 inhibitor that increases the production of insulin by the beta cells of the pancreas while reducing

Read more

AskNadia: Are the Nitrates in My Low Carb Diet Bad

Dear Nadia, I am on a low carb diet for my diabetes. My blood sugars are good, but I worry about the nitrates in the meat? Sylvia PA Dear Sylvia, The nitrate food additive is of great concern to many people. To make this issue more complex, you should know that nitrates are not unique to commercially prepared cured meats. They can also be found

Read more

Warning Letters Issued to Illegally Sold Diabetes Treatments

Recently, FDA launched an initiative to counter these illegally sold products aimed at consumers who have diabetes. In addition to evaluating numerous consumer complaints, FDA surveyed the marketplace for illegally sold products promising to treat diabetes and its complications. In July 2013, FDA issued letters warning 15 companies about selling products for diabetes in violation of federal law. These products are sold as dietary supplements;

Read more

Insulin Pens are Not for Sharing: Diabetes Health Editor’s Note

The FDA reminds us why sharing insulin pens may create long terms health concerns. While some people do save on costs when reusing and or sharing insulin pens, the possible long term complications are not worth the savings. By Food and Drug Administration The Food and Drug Administration (FDA) is reminding health care professionals and patients that insulin pens and insulin cartridges should not be

Read more

FDA Approves Once-weekly Trulicity to Treat Type 2 Diabetes

The U.S. Food and Drug Administration recently approved Trulicity, a once-weekly injectable to treat adults with type 2 diabetes. Also known as dulaglutide, Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps normalize blood sugar levels by encouraging the release of insulin, which helps the body better use available blood glucose, while suppressing the stimulation of glucose production. During the six-trial testing phase of

Read more

Eylea Earns FDA Approval To Treat Diabetic Macular Edema

The U.S. Food and Drug Administration has approved the eye drug Eylea for the treatment of diabetic macular edema, according to the drug makers Regeneron Pharmaceuticals, Inc. Diabetic macular edema (DME) is a common complication for those with diabetes. Of the 29.1 million Americans with diabetes, 1.5 million have been diagnosed with DME. This occurs when the blood vessels of the retina are damaged due

Read more

FDA Delays Decision on Inhaled Insulin

The Food and Drug Administration (FDA) has delayed until July 15th making a decision on whether to allow the inhaled insulin Afrezza entry into the American market. Manufactured by Valencia, Calif.-based MannKind Corp., Afrezza uses a small inhaler that delivers insulin powder into the lungs. It is aimed at both type 1 and type 2 people with diabetes. The technology takes advantage of the lungs’

Read more